<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328470</url>
  </required_header>
  <id_info>
    <org_study_id>PIANO-CKD2</org_study_id>
    <nct_id>NCT01328470</nct_id>
  </id_info>
  <brief_title>Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease</brief_title>
  <acronym>CKD</acronym>
  <official_title>Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Impaired renal function is associated with reduced responsiveness to clopidogrel. There are
      no studies which have shown a means by which to overcome platelet hyporesponsiveness in
      patients with chronic kidney disease (CKD). The purpose of this study was to determine the
      functional impact of cilostazol in patients with CKD undergoing hemodialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of this study is to evaluate the effects of platelet responsiveness to clopidogrel
      or cilostazol in CKD patients undergoing hemodialysis. The differences in platelet activation
      markers are also evaluated before and after clopidogrel or cilostazol administration. The
      investigators will perform a prospective, randomized study to compare the degree of platelet
      inhibition and platelet activation markers by adjunctive cilostazol (100 mg twice daily)
      compared to clopidogrel (75 or 150 mg/day) in CKD patients undergoing hemodialysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The differences of platelet aggregation according to the anti-platelet therapy.</measure>
    <time_frame>14 days</time_frame>
    <description>Platelet function was assessed with light transmittance aggregometry and the VerifyNowTM P2Y12 assay.
High on-treatment platelet reactivity was defined as 5 μmol/L of ADP-induced Aggmax &gt; 50%.
Inhibition of platelet aggregation (IPA) was defined as the percent decrease in aggregation values obtained at baseline and after treatment.
VerifyNow-P2Y12 assay results are also assessed and expressed in P2Y12 reaction units (PRUs) and the percentage of inhibition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of platelet activation markers according to the anti-platelet therapy</measure>
    <time_frame>14 days</time_frame>
    <description>Markers of platelet activation (soluble CD40 ligand [sCD40L] and soluble P-selectin [sP-selectin]) were assessed at baseline and after 14 days of anti-platelet therapy.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>clopidogrel 75 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 75 mg/day for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel 150 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 150 mg/day for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adjunctive cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive co-administration of adjunctive cilostazol (100 mg twice daily) and clopidogrel (75 mg/day; [group 3, 20 patients]) for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75mg clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group undergoing PCI for stable angina will be also maintained on clopidogrel (75 mg/day for 14 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel, cilostazol</intervention_name>
    <description>Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days</description>
    <arm_group_label>clopidogrel 75 mg/day</arm_group_label>
    <arm_group_label>clopidogrel 150 mg/day</arm_group_label>
    <arm_group_label>adjunctive cilostazol</arm_group_label>
    <arm_group_label>75mg clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>pletaal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery
             disease

        Exclusion Criteria:

          -  known allergies to aspirin, clopidogrel, or cilostazol thienopyridine use before
             enrollment

          -  concomitant use of other anti-thrombotic drugs (oral anticoagulants and dipyridamole)

          -  platelet count &lt;100 x 106/μL

          -  hematocrit &lt; 25%

          -  liver disease (bilirubin &gt; 2 mg/dl)

          -  active bleeding or bleeding diathesis

          -  gastrointestinal bleeding within the last 6 months

          -  hemodynamic instability

          -  acute coronary or cerebrovascular event within 3 months

          -  malignancy

          -  concomitant use of a cytochrome P450 inhibitor or a non-steroidal anti-inflammatory
             drug

          -  recent treatment (&lt;30 days) with a glycoprotein IIb/IIIa antagonist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weon Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyung Hee University</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009 Nov 1;104(9):1292-5. doi: 10.1016/j.amjcard.2009.06.049.</citation>
    <PMID>19840579</PMID>
  </results_reference>
  <results_reference>
    <citation>Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007 Feb 13;115(6):708-16. Epub 2007 Jan 29.</citation>
    <PMID>17261652</PMID>
  </results_reference>
  <results_reference>
    <citation>Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabaté M, Ferreiro JL, Ueno M, Jimenez-Quevedo P, Alfonso F, Bass TA, Macaya C, Fernandez-Ortiz A. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol. 2010 Mar 16;55(11):1139-46. doi: 10.1016/j.jacc.2009.10.043.</citation>
    <PMID>20223369</PMID>
  </results_reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <last_update_submitted>April 1, 2011</last_update_submitted>
  <last_update_submitted_qc>April 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kyunghee University</name_title>
    <organization>Kyunghee University</organization>
  </responsible_party>
  <keyword>platelet</keyword>
  <keyword>cilostazol</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

